Text Size

Pharmacotherapy and Intensive Treatment of Drug Abuse - 1

This study has been completed.
Sponsor:
Collaborators:
National Institute on Drug Abuse (NIDA)
Department of Veterans Affairs
Information provided by (Responsible Party):
University of Kansas
ClinicalTrials.gov Identifier:
NCT00000217
First received: September 20, 1999
Last updated: March 19, 2013
Last verified: March 2013
History of Changes
  Purpose

The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.


Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
 Drug: Carbamazepine
 Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pharmacotherapy and Intensive Treatment of Drug Abuse

Resource links provided by NLM:

MedlinePlus related topics: Anxiety
U.S. FDA Resources

Further study details as provided by University of Kansas:

Primary Outcome Measures:
  • Drug use
  • Effectiveness of medication
  • Level of pharm
  • Retention
  • Depression, anxiety

Estimated Enrollment: 0
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000217

Locations
United States, Missouri
University of Kansas
Kansas City, Missouri, United States, 64128
Sponsors and Collaborators
University of Kansas
National Institute on Drug Abuse (NIDA)
Department of Veterans Affairs
Investigators
Principal Investigator: William Haning, M.D. University of Kansas
  More Information

No publications provided

Responsible Party: University of Kansas
ClinicalTrials.gov Identifier: NCT00000217     History of Changes
Other Study ID Numbers: NIDA-06954-1, R18DA006954, R18-06954-1
Study First Received: September 20, 1999
Last Updated: March 19, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Substance-Related Disorders
Cocaine-Related Disorders
Mental Disorders
Carbamazepine
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
 Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anticonvulsants
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs

ClinicalTrials.gov processed this record on May 21, 2013